Charles Schwab
VBIV

Charles Schwab’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Charles Schwab’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,377
Closed -$86.8K – 3643
2023
Q2 		$86.8K Sell
26,377
-21,915
-45% -$66.2K ﹤0.01% 3359
2023
Q1 		$439K Sell
48,292
-491
-1% -$6.96K ﹤0.01% 2991
2022
Q4 		$572K Buy
48,783
+1,147
+2% +$20.2K ﹤0.01% 2963
2022
Q3 		$1.01M Sell
47,636
-1,413
-3% -$38.1K ﹤0.01% 2792
2022
Q2 		$1.19M Sell
49,049
-5,775
-11% -$197K ﹤0.01% 2731
2022
Q1 		$2.73M Buy
54,824
+1,452
+3% +$71.7K ﹤0.01% 2546
2021
Q4 		$3.75M Buy
53,372
+876
+2% +$73.8K ﹤0.01% 2492
2021
Q3 		$4.9M Buy
52,496
+1,309
+3% +$124K ﹤0.01% 2384
2021
Q2 		$5.14M Buy
51,187
+1,529
+3% +$149K ﹤0.01% 2342
2021
Q1 		$4.63M Buy
49,658
+2,912
+6% +$295K ﹤0.01% 2337
2020
Q4 		$3.86M Buy
46,746
+2,084
+5% +$178K ﹤0.01% 2346
2020
Q3 		$3.83M Buy
44,662
+29,558
+196% +$3.44M ﹤0.01% 2211
2020
Q2 		$1.41M Buy
15,104
+828
+6% +$45.6K ﹤0.01% 2536
2020
Q1 		$407K Hold
14,276
– – ﹤0.01% 2780
2019
Q4 		$592K Buy
14,276
+7,581
+113% +$166K ﹤0.01% 2762
2019
Q3 		$95K Hold
6,695
– – ﹤0.01% 3096
2019
Q2 		$235K Buy
6,695
+5,819
+664% +$316K ﹤0.01% 3066
2019
Q1 		$50K Buy
+876
New +$47.4K ﹤0.01% 3129
2018
Q2 		– Sell
-1,940
Closed -$204K – 3156
2018
Q1 		$204K Hold
1,940
– – ﹤0.01% 2989
2017
Q4 		$249K Buy
1,940
+513
+36% +$63.1K ﹤0.01% 2934
2017
Q3 		$165K Hold
1,427
– – ﹤0.01% 3036
2017
Q2 		$187K Buy
+1,427
New +$193K ﹤0.01% 3040

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab's VBIV Position: Q3 2023 in Review

Charles Schwab sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2023, closing a stake of 26,377 shares — an estimated $86.8K sold.

Charles Schwab first reported a position in VBIV in Q2 2017 and held it in 22 quarters. The position peaked at $5.14M in Q2 2021. 37 funds tracked by Wall St. Rank hold VBIV as of Q3 2023.

  • Charles Schwab reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2023 after selling out during the quarter.
  • Charles Schwab sold 26,377 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2023, an estimated $86.8K.
  • Charles Schwab first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 22 quarters.
  • Charles Schwab's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $5.14M in Q2 2021.
  • 37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2023.

Based on Charles Schwab's 13F filing for Q3 2023, filed 8 Nov 2023.